Spruce Biosciences Past Earnings Performance
Past criteria checks 0/6
Spruce Biosciences's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 102.7% per year.
Key information
-25.6%
Earnings growth rate
61.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 102.7% |
| Return on equity | -62.6% |
| Net Margin | -475.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Spruce Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 10 | -48 | 13 | 0 |
| 30 Sep 23 | 7 | -49 | 13 | 47 |
| 30 Jun 23 | 4 | -48 | 12 | 35 |
| 31 Mar 23 | 2 | -47 | 12 | 35 |
| 31 Dec 22 | 0 | -46 | 12 | 0 |
| 30 Sep 22 | 0 | -44 | 12 | 33 |
| 30 Jun 22 | 0 | -44 | 12 | 15 |
| 31 Mar 22 | 0 | -44 | 11 | 24 |
| 31 Dec 21 | 0 | -42 | 11 | 31 |
| 30 Sep 21 | 0 | -41 | 11 | 30 |
| 30 Jun 21 | 0 | -40 | 10 | 29 |
| 31 Mar 21 | 0 | -34 | 8 | 26 |
| 31 Dec 20 | 0 | -30 | 6 | 24 |
| 30 Sep 20 | 0 | -24 | 3 | 21 |
| 30 Jun 20 | 0 | -17 | 2 | 15 |
| 31 Mar 20 | 0 | -15 | 2 | 12 |
| 31 Dec 19 | 0 | -13 | 2 | 11 |
Quality Earnings: SPRB is currently unprofitable.
Growing Profit Margin: SPRB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPRB is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare SPRB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPRB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: SPRB has a negative Return on Equity (-62.63%), as it is currently unprofitable.